

Anticipating the fate and impact of organic environmental contaminants: A new approach applied to the pharmaceutical furosemide

Céline Laurencé, Michael Rivard, Thierry Martens, Christophe Morin, Didier Buisson, Sophie Bourcier, Michel Sablier, Mehmet Oturan

▶ To cite this version:

Céline Laurencé, Michael Rivard, Thierry Martens, Christophe Morin, Didier Buisson, et al.. Anticipating the fate and impact of organic environmental contaminants: A new approach applied to the pharmaceutical furosemide. Chemosphere, 2014, 113, pp.193-199. 10.1016/j.chemosphere.2014.05.036. hal-04049058

HAL Id: hal-04049058 https://hal.science/hal-04049058

Submitted on 28 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	Anticipating the Fate and Impact of	of Organic Environmental								
2	Contaminants: A New Approach Ap	plied to the Pharmaceutical								
3	Furosemide									
4										
5	Céline Laurencé, ^a Michael Rivard, ^a Thierry Martens	s ^{a, *} Christophe Morin, ^b Didier Buisson, ^c								
6	Sophie Bourcier, ^d Michel Sablier, ^{d,e} d	and Mehmet A. Oturan, ^f *								
7										
8										
9 10	^a Université Paris-Est, Institut de Chimie UMR CNRS UPEC 7182 - 94									
11 12 13	^b Université Paris-Est, Laboratoire Croissance Ré EAC CNRS 7149 - UPEC, 94010									
14 15 16	°Muséum National d'Histoire Naturelle, Unité Molécules de Communication et Adaptation des Microorganismes, UMR CNRS MNHM 7245 - 75005 Paris, France									
17 18 19	^d Ecole Polytechnique, Laboratoire des Mécanismes Réactionnels UMR CNRS Ecole Polytechnique 7651 - 91128 Palaiseau cedex, France									
20 21 22 23 24	^e Muséum National d'Histoire Naturelle, Centre de Recherche sur la Conservation des Collections, USR CNRS MNHN 3224 - 75005 Paris, France									
25 26 27	^f Université Paris-Est, Laboratoire Géomatériaux et Environnement, EA 4508 UPEMLV, 77454 Marne-la-Vallée, France									
28										
29		1 6 11 4								
30	Paper submitted to Chemosphere	nere for publication								
31										
32										
33	* Corresponding authors:									
34	Mehmet A. Oturan	Thierry Martens								
35	Email: mehmet.oturan@univ-paris-est.fr	Email: martens@icmpe.cnrs.fr								
36	Phone:+33 (0)1 49 32 90 65	Phone: +33 (0)1 49 78 11 56								
37	Fax: +33(0)1 49 32 91 37	Fax: +33 (0)1 49 78 11 48								
38										

- **39 ABSTRACT**
- 40

41 The presence of trace levels of organic contaminants in the environment is currently an 42 environmental concern. When these contaminants are subjected to environmental 43 transformations, environmental transformation products (ETPs) are obtained, whose 44 structures often remain unknown. The absence of information concerning these new 45 compounds makes them unavailable and consequently makes their environmental detection as 46 well as their (eco)toxicological study impossible. This report describes a multidisciplinary 47 approach that seeks to both anticipate the fate and evaluate the impact of organic 48 environmental contaminants.

Our approach consists of three steps. First, isolated and fully characterized transformation products (TPs) of the parent molecule are obtained. This step requires classical organic synthesis and focuses on providing standards of the compounds. In the second step, the parent molecule is subjected to environmentally relevant transformations to identify plausible ETPs. The detection of previously characterized TPs allows the concomitant identification of plausible ETPs. The third step is devoted to the toxicological evaluation of the identified plausible ETPs.

56 Such an approach has recently been applied to furosemide and has allowed the identification 57 of its main TPs. This report now seeks to identify and evaluate toxicologically plausible ETPs 58 of this drug, which is also known as an environmental contaminant.

59

60 Keywords: Furosemide, Electro-Fenton, Bioconversion, Toxicity

1. INTRODUCTION

63

62

64 Emerging pollutants are a class of compounds that result from human activity, are 65 detected in the environment and whose impact on ecosystems remains unknown (Levi, 2009). 66 These pollutants consist of compounds that were originally developed as pharmaceuticals and 67 personal care products (PPCPs) (Daughton, 2002; Khetan and Collins, 2007; Fatta-Kassinos 68 et al., 2011a) bactericides or industrial additives (Jurado et al., 2012; Rodil et al., 2012). 69 Regarding the pharmaceuticals, the progress made in trace analysis during the last decade 70 (Buchberger, 2011) has allowed their detection and quantification in the effluents of sewage 71 treatment plants (STPs), rivers, ground water, and sometimes even in drinking water 72 (Heberer, 2002; Kuemmerer, 2004). The presence of pharmaceuticals in the environment 73 mainly occurs after their excretion and results from an incomplete degradation in STPs 74 (Deblonde et al., 2011). Despite their low environmental concentrations, which are generally 75 measured to be less than human therapeutic levels (from ng/L to $\mu g/L$), the continuous release 76 of these substances makes them pseudo-persistent, thus presenting a risk of ecotoxicity or 77 chronic toxicity for non-target organisms (Daughton and Ternes, 1999).

78 Assessing the impact of the presence of drugs (i.e., molecules designed to exert a 79 biological effect) on aquatic biota requires an ecotoxicity or a chronic toxicity to be 80 univocally associated with a perfectly identified chemical structure (or alternatively, to a well-81 defined mixture of molecules). For this purpose, biological models have been applied to 82 molecules whose presence in the environment had been previously highlighted (Henschel et 83 al., 1997). However, the primary limitation of such studies is that they do not consider the 84 environmental transformation products (ETPs), i.e., compounds stemming from the parent 85 molecule and likely to appear in the environment consecutively to (a)biotic transformations. 86 Attempts to identify ETPs from the analysis of complex environmental matrices, such as soils, 87 sediments or biota, have been demonstrated to be prone to failure (Ibanez et al., 2004; 88 Richardson, 2010). Under these conditions, chromatographic techniques coupled with mass 89 spectrometry in "full-scan" detection mode cannot achieve the detection limits required to 90 characterize these unknown compounds that are present at trace levels. In the absence of 91 characterization, the majority of ETPs remain ill-defined, thus ruling out the evaluation of 92 their (eco)toxicities, which is problematic because the toxicity of ETPs may exceed that of 93 their parent molecules (Dirany et al., 2011; Fatta-Kassinos et al., 2011b; Dirany et al., 2012). 94 In the case of pharmaceuticals, metabolites are a class of ETPs whose structure can be rather 95 well-anticipated (Lohmann and Karst, 2008), and these have already been the subject of

environmental detections (Celiz et al., 2009; Mompelat et al., 2009). Further investigations 96 97 focusing on the identification of new ETPs and the assessment of their impact has led to the 98 development of various strategies (Escher and Fenner, 2011). With this aim, experiments that 99 mimic the transformations that drugs undergo in the environment have been developed 100 (Ziylan and Ince, 2011). These experiments, which were applied to the parent molecule, 101 resulted in transformation products (TPs) assumed to be real (at least similar to) ETPs. Such 102 experiments typically proceed by electro-Fenton (Oturan et al., 1999), photodegradation 103 (Packer et al., 2003) or biodegradation (Ericson, 2010; Gauthier et al., 2010). Because of such protocols and thanks to the means now available, elucidating the structure of these 104 105 compounds is possible. Nevertheless, authentication of the structure requires the use of 106 standards either commercially available or synthesized (Schulze et al., 2010; Svanfelt and 107 Kronberg, 2011). In the absence of isolated compounds, (eco)toxicological studies are 108 conducted on mixtures of TPs resulting from the degradation of the parent molecule. Interestingly, examples of (eco)toxicological evaluations of fully characterized TPs obtained 109 110 and isolated after the degradation of the parent pharmaceutical remain scarce (Isidori et al., 111 2006).

112 In this report, we describe a new approach that enables both the identification of plausible 113 ETPs and their toxicological evaluation. Because the main difficulty in studying the fate of 114 drugs in the environment lies in the lack of authentic samples of their ETPs, we propose a 115 new stepped approach. The first step consists of isolating the TPs of a drug that is known to 116 be an environmental contaminant. This step, which requires the tools of organic synthesis, 117 focuses on providing fully characterized standards and the development of methods for their 118 detection in complex mixtures. In the second step, the contaminant is submitted to 119 environmentally relevant transformations, i.e., processes that are representative of the 120 transformations undergone by contaminants in the environment. By highlighting previously 121 characterized TPs, this step allows the identification of plausible ETPs. In the third step, a 122 toxicological study is initiated on each of the TPs that are identified as plausible ETPs.

In a recent work, we described the behavior of furosemide 1 (fig 1) under oxidative conditions (Laurence et al., 2011). This drug, which has been widely used as a diuretic since the nineteen sixties, is one of the forty compounds having the highest risk with a predicted environmental concentration greater than 100 ng/L (Besse and Garric, 2008). Poorly metabolized and eliminated either unmodified or as glucuronide conjugate (Lee et al., 1997) (which releases furosemide after hydrolysis), this drug has been detected at concentration ranges between 61 and 200 ng/L in European rivers (Castiglioni et al., 2006; Khalaf et al., 130 2009). During the course of our preliminary study, three TPs of furosemide were identified: 131 furfural 2, saluamine 3 (both resulting from the oxidation of the amino group) and a 132 zwitterionic pyridinium 4 (resulting from the oxidation of the furan ring). These three TPs, 133 which are obtained by anodic oxidation, have been isolated and fully characterized, thereby 134 allowing their detection by LC-MS in complex mixtures.

This study seeks to confirm whether these three TPs, which were obtained without any environmental relevance, are indeed plausible ETPs. For this purpose, environmentally relevant degradation pathways were applied to furosemide. To be representative of the transformations likely to occur in the environment, two protocols were selected. The first protocol is abiotic and uses an electrochemical advanced oxidation process (electro-Fenton); the second protocol is biotic and requires microorganisms. The TPs identified as plausible ETPs were then subjected to a preliminary toxicological study.

- 142
- 143

2. MATERIAL AND METHODS

144

145 **2.1 Chemicals**

146

Furosemide (> 99.0%) was purchased from TCI Europe N.V. Furfural (99%) and 1-Methyl-147 148 4-phenylpyridinium iodide (MPP⁺) were purchased from Sigma-Aldrich. Saluamine 3 and 149 pyridinium 4 employed for the toxicological evaluation and required as standards for the 150 analysis of complex mixtures were prepared as previously described (Laurence et al., 2011). 151 Essential Medium (DMEM), fetal bovine serum Dulbecco's Minimal (FBS), 152 penicillin/streptomycin, trypsin-EDTA solution and phosphate buffered saline (PBS) were 153 purchased from GibcoBRL (France). The caspase fluorogenic substrate N-Acetyl-Asp-Glu-154 Val-Asp-7-amido-4-trifluoromethylcoumarin (Ac-DEVD-AFC) was purchased from 155 Calbiochem (France). Sodium chloride (NaCl), 4-(2-hydroxyethyl)-1-156 piperazineethanesulfonic acid (HEPES), triton X-100, dithiothreitol (DTT), and 3-(4,5-157 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (Germany). 158

159

160 **2.2 Analytical procedure**

ESI-MS/MS analyses were conducted using a Q-TOF Premier instrument equipped with 162 163 a Z-spray electrospray source (Waters, Saint Quentin-en-Yvelines, France) operating in the 164 positive mode. For fragmentation studies, solutions were introduced into the electrospray 165 ionization source using a syringe pump at an infusion rate of 10 µL/min. To investigate the 166 degradation products, the sample was analyzed using a 2690 liquid chromatography module 167 from Waters (Saint Quentin-en-Yvelines, France) coupled with a Q-TOF premier mass 168 spectrometer. The employed analytical column was a C18 Atlantis T3, 3 µm, 150 x 2.1 mm 169 (Waters, Saint Quentin-en-Yvelines, France). The HPLC solvents were acetonitrile with 0.1% 170 formic acid (A) and water with 0.1% formic acid (B). The following linear gradient elution 171 program was applied: 20% of A for 11 min and 100% of A from 11.1 to 20 min. Then, before 172 the next injection cycle, the column was reconditioned with 20% of A for 10 min. The 173 effluent was introduced at a rate of 0.2 mL/min into the Z-spray interface for ionization. The 174 following three acquisition modes were used to characterize each compound: (i) full-scan 175 mode in V-mode; (ii) MS/MS of the precursor ion and (iii) full-scan in the W-mode for high 176 resolution. The full-scan acquisition mode allowed the cone voltage to be optimized to obtain 177 maximum intensity for the precursor ion. Several MS/MS spectra were recorded to obtain the 178 decomposition pathways.

The cone voltage was adjusted for each ion of interest that was generated in the ion 179 180 source. The ion source parameters were adjusted as follows to optimize the ion signals: the 181 cone voltage was set between 20 to 80 V while the capillary voltage was set to 2.6 kV. 182 Typical values for the other source parameters were as follows: extraction cone, 1.7 V; ion guide, 3 V; source and desolvation temperatures were set at 80 °C and 250 °C for direct 183 infusion and at 100 °C and 450 °C for LC-MS studies, respectively. Nitrogen was used as 184 185 both nebulizing and desolvation gases. The gas flow rates were dependent on the introduction 186 mode; they ranged from 20 L/h to 300 L/h for direct introduction and from 70 L/h to 700 L/h for LC-MS. For LC-MS analysis, the injected volume of sample was 10 µL. Argon was used 187 as a collision gas at a flow of 0.28 mL/min, which corresponds to a pressure of ca. 4 10^{-3} 188 189 mbar. To record the MS/MS spectra of ions, the collision energies were varied between 2 to 190 30 eV for each compound to obtain their primary characteristic ions. For accurate mass 191 measurements, the analyses were performed using W-mode and an independent reference 192 spray via the LockSpray interface. Sulfadimethoxine was used as the lock mass compound at 193 a flow rate of 10 µL/min. The LockSpray frequency was set at 10 s, and data for the reference 194 compounds were averaged over 10 spectra/min. Accurate masses and elemental compositions for all ions were obtained using the MassLynx instrument software. The ion used for the masscorrection was m/z 311.0814.

197

198 **2.3 Electro-Fenton**

199

200 Experiments were conducted in an open, cylindrical and undivided glass cell of 6 cm 201 diameter and 250 mL capacity. This cell was equipped with a cylindrical Pt mesh (4.5 cm 202 height, 3.1 cm internal diameter) as an anode and a large surface area (14 cm x 4.5 cm each 203 side, 0.5 cm width) carbon felt (Carbon-Lorraine, France) as a cathode. The anode was 204 centered in the electrochemical cell and surrounded by the cathode, which covered the inner 205 wall of the cell. Electrolyses were conducted under a constant current applied by a Hameg 206 HM8040 triple power supply. H₂O₂ was produced from the reduction of O₂ dissolved in the 207 solution. Continuous saturation of this gas at atmospheric pressure was ensured by bubbling compressed air. 220 mL of solutions containing 0.1 to 0.3 mM furosemide and 0.5 mM Fe²⁺ 208 209 at the optimum pH value of 3.0 were electrolyzed at a constant current (30-350 mA) at room 210 temperature. The decrease in the concentration of furosemide and the formation of oxidation 211 intermediates were followed using a Merck Lachrom HPLC chromatograph composed of a 212 degasser (L-7614), an injection pump (L-7100 equipped with a 20 µL injection loop), a 213 reverse phase RP-18 Purospher column (5 μ m, 4.6 mm× 25 cm) placed into a L-7350 oven set 214 to 40 °C and a photodiode array detector (L-4755) selected at 280 nm. The mobile phase 215 consisted of a mixture of methanol and phosphoric acid (55/45 (v/v)) at a pH of 3. Elution 216 was performed in isocratic mode with a flow rate of 0.7 mL/min. Identification of aromatic 217 intermediates was conducted by comparing the retention times with that of authentic 218 compounds and UV-Vis spectra. The analyses were monitored using the EZChrom Elite 219 software package.

220

221 **2.4 Bioconversion**

222

Microorganisms, including 48 fungi and 24 bacteria, were cultured in liquid medium (25 mL) containing in g/L: yeast extract (Conda) 4, malt extract (Conda) 10, soybean peptones (OrganoTechnie) 5, and glucose 16. The process of selection involved six series of 12 microorganisms. After sufficient growth, the biomasses were harvested by centrifugation (bacteria) or filtration (fungi) and suspended in 12 mL of a 0.1 M sodium citrate buffer (pH 5). For each series, four incubation mixtures (3 fungi and 2 bacteria) were created using the suspensions (4 mL, total volume of 20 mL). Furosemide was dissolved in *N*,*N*dimethylformamide (0.066 mg/ μ L) and 60 μ L of this solution were added to the incubation mixtures (final concentration 0.2 mg/ml). Biotransformations were performed under an air atmosphere at 27 °C and 200 rpm and monitored by HPLC and MS. Aliquots (culture medium and biomass; 0.8 mL) were withdrawn every two days, diluted with methanol (200 μ L), mixed vigorously and centrifuged at 13,000 g for 5 minutes. The resulting supernatants were micro-filtered (0.45 μ m) before analysis.

- 236
- 237

2.5 Toxicity measurements

238

239 2.5.1 MTT Cell Viability Assay

240

241 Human neuroblastoma cells (SH-SY5Y) (ATCC CRL2266) were cultured in DMEM (in 75 242 mL flasks), containing 4.5 g/L glucose and supplemented with 1% penicillin/streptomycin and 10% FBS, at 37 °C in a humidified atmosphere of 5% CO₂. Cell viability was measured using 243 the MTT assay in 96-well plates at a cell density of 8×10^4 cells/mL. The cells were exposed 244 to different compounds (1, furfural 2, 3 and 4) at various concentrations (from 1 to 1000μ M). 245 246 All drugs were dissolved in a mixture of DMSO and DMEM (1/1 (v/v)) in order to obtain a 247 10⁻¹ M stock solution. All controls were carried out using the same solvent mixture. The final 248 solution contained no more than 0.5% (v/v) of DMSO. After 24, 48, 72 and 96 h of exposure, 249 MTT (20 µL, 5 mg/mL) was added to each well. Following incubation at 37 °C for 2 h, the 250 supernatants were carefully removed and 200 µL of DMSO were added. The optical density 251 (OD) value of each well was read using a micro-plate reader (TECAN Infinite M1000) at a 252 wavelength of 570 nm. Cell viability was calculated as a percentage of the control.

- 253
- 254 2.5.2 Caspase-3 activity
- 255

The caspase-3 activity was assessed by following the cleavage of the fluorogenic substrates Ac-DEVD-AFC. Treated cells were harvested through trypsinization using 0.05% trypsin and 0.53 mM EDTA at 37 °C in a humidified atmosphere containing 5% CO₂ for 4 min. Trypsinization was terminated by addition of 20% FBS, the cell suspension was then centrifuged, the supernatant discarded and the pellet washed with $1 \times PBS$ (CaCl₂-, MgCl₂free) (Gibco, Invitrogen). The cell pellet was gently suspended in a buffer containing 30 mM HEPES, 0.3 mM EDTA, 100 mM NaCl, 0.15% Triton X-100 and 10 mM DTT and then centrifuged. The supernatant was used for the assay. The fluorogenic substrates were added at a final concentration of 100 mM. The samples were gently mixed and incubated in the dark at 37 °C for 1 h. Fluorescence intensity of the samples was measured at an excitation λ of 400 nm and emission λ of 505 nm using a fluorescence micro-plate reader (TECAN infiniteTM M1000).

268

269	
270	

2.5.4 Data analysis

- Data were expressed as the mean \pm SEM. Comparisons among groups were conducted using an ANOVA (F-test) test. Bonferroni adjusted t-tests were used for multiple group comparisons and the unpaired t-test was used for single comparisons. A two-tailed p<0.05 was selected to indicate a statistically significant difference. All values were calculated using the GraphPad Prism 5.00 software package (GraphPad Software, San Diego, CA).
- 276
- **3. RESULTS**
- 278

3.1 Electro-Fenton

280

In the first step, furosemide was subjected to electro-Fenton oxidative degradation. This method is based on the *in situ* and catalytic production of hydroxyl radicals (•OH) from the electrochemically assisted Fenton's reaction (Eqs. 1-3).

- 284
- $285 \qquad O_2 + 2H^+ + 2e^- \rightarrow H_2O_2 \qquad (1)$
- $Fe^{3+} + e^{-} \rightarrow Fe^{2+}$

287
$$H_2O_2 + Fe^{2+} \rightarrow Fe^{3+} + OH^- + \cdot OH$$
(3)

288

The hydroxyl radical is a very powerful oxidizing agent, and it non-selectively reacts with organic molecules to lead to the formation of abiotic TPs. In the treatment strategy, the operating parameters were established to further oxidize these intermediates until they reached their ultimate degree of oxidation, i.e., their mineralization (Eq. 4) (Oturan et al., 2000; Sires et al., 2007; Brillas et al., 2009). This process has been successfully applied for

(2)

the treatment of toxic/persistent pollutants and particularly for the removal of pharmaceutical
pollutants from water (Ozcan et al., 2008; Dirany et al., 2010; Sires et al., 2010).

- 296
- 297

•OH + organic pollutants
$$\rightarrow$$
 [abiotic TPs] \rightarrow mineralization (4)

298

As stated above, the electro-Fenton process was used to mimic the abiotic transformations that are likely to occur in the environment. Contrary to the abatement (treatment) strategy, the inhibition of oxidation kinetics was consequently required to allow the accumulation of the abiotic TPs. Briefly, this inhibition consisted of applying a small current (for weakening the rate of Eqs. 1 and 2) and using a high concentration of catalyst (Fe²⁺) to favor the waste reaction between •OH and Fe²⁺ (Eq. 5), thus lowering the concentration of •OH and consequently the oxidation rate of the intermediates.

- 306
- 307
- 308

$$\bullet OH + Fe^{2+} \rightarrow Fe^{3+} + OH^{-}$$
(5)

309 This strategy was applied under a pH of 3 at room temperature to a 230 mL aqueous 310 solution of furosemide (0.3 mM) using a current of 50 mA between a Pt anode and a carbon-311 felt cathode in the presence of Fe^{2+} (0.5 mM) as a catalyst. After 5 min of electrolysis, HPLC 312 analysis of an aliquot revealed the presence of several abiotic TPs. Preparative 313 chromatography on an RP 18 column allowed the isolation of the main compound and its characterization by ¹H-NMR. After comparison with the previously obtained data, the aniline 314 315 derivative 3 (Fig 1) was unambiguously identified. The co-product of this oxidation process, 316 the furfural, was also identified among the other abiotic TPs by comparison with the HPLC 317 chromatogram and UV spectrum of an authentic sample.

Monitoring the electro-Fenton treatment of furosemide by HPLC and analyzing aliquots by LC-MS confirmed the formation of compound **3** with the presence of the m/z 251 protonated molecular ion (see SI §2). Two other compounds with protonated molecular ions at m/z 329 and m/z 345 were also observed. The structure associated with m/z 329 was confirmed by comparison with previously obtained data and unambiguously identified as pyridinium **4** (see SI §4). The CID mass spectrum analysis led to the proposal of structure **A** (see SI §5, 6) for m/z 345 (Fig 2a).

To identify further oxidation products of furosemide, electro-Fenton oxidation was performed on pyridinium **4**. Under these conditions, the compound previously associated with 327 structure A was again observed (see SI §5) as well as the aniline derivative 3 (see SI §3). The 328 oxidation of the pyridinium ring of 4, which leads to intermediates such as A, may explain the 329 formation of the latter. Meanwhile, LC-MS analysis of the reaction mixture allowed the 330 observation of two compounds with pseudo-molecular ions at m/z 317 and 282 for which 331 structures B1 and C1 (Fig 2b) have been, respectively proposed (see SI §7-10). The same 332 experiment also revealed the presence of two isomers of B1 and C1. The analysis of the CID 333 mass spectra did not allow their univocal characterization, which leads to the proposal of the 334 regioisomers B2 or B3 for m/z 317 and C2 or C3 for m/z 282.

335

336 3.2 Bioconversion

337

338 Furosemide is poorly metabolized by humans; however, this does not exclude the 339 possibility for non-target organisms disposing of the appropriate enzymatic equipment to 340 achieve the transformation of furosemide. One way to fairly accurately identify the spectrum 341 of biotic TPs arising from furosemide consists of subjecting this molecule to microbial 342 transformation (bioconversion). The enzymes that are present in many microbial strains allow 343 access to a wide range of biotransformation products. This approach, which is especially used in the preparation of mammalian metabolites (Smith and Rosazza, 1975; Azerad, 1999; Asha 344 345 and Vidyavathi, 2009), requires the selection of active microorganisms (Li et al., 2008; 346 Marvalin and Azerad, 2011).

To obtain the biotic TPs of furosemide, a selection of microorganisms among seventytwo strains of bacteria and fungi was performed. To complete the screening using minimal time and assays, we used our recently developed combinatorial approach (Fromentin et al., 2012; Joyeau et al., 2013). This method is based on incubating the substrate in the presence of five microorganisms (three fungi and two bacteria) in a reaction buffer. After furosemide was added to the suspensions, the biotransformations were monitored by HPLC and MS analyses of aliquots collected every forty-eight hours.

This strategy allowed identification of four microorganisms capable of performing the biotransformation of furosemide as well as the observation of two major biotic TPs. Saluamine **3**, which resulted from the hydrolysis of the intermediate hemiaminal, was obtained with a yield of 25-30% after four days of incubation with the bacteria *Agrobacterium tumefaciens (Rhizobium radiobacter* CIP 67.1) and *Arthrobacter ureafaciens* CIP 67.3. This result confirmed the ability of the microorganisms to oxidize the α -position of the amino group of furosemide, as previously observed (Hezari and Davis, 1992). The absence of furfural may be explained by the ability of some microorganisms to degrade it (Koopman et al., 2010). The fungus *Aspergillus candidus* ATCC 20023 produced pyridinium **4** in moderate yields after eight days (see SI §4). The fungus *Cunninghamella echinulata* var. *elegans* ATCC 9245 fully metabolized furosemide in six days to yield a mixture of both compounds. In some cases, the compound associated with structure **A** was also observed as a minor biotic TP (see SI §5). Further investigations are in progress to optimize the production of this TP to isolate it and confirm its structure.

- 368
- 369

3.3 Toxicological evaluation of plausible ETPs

370

The evaluation on the neuroblastoma cell line (SH-SY5Y) of furosemide 1 revealed no activity on the tested cells after 24 and 48 h. However, after 72 h, a slight inhibition of approximately 20% of the cell survival was observed, which is possibly explained by the action of furosemide on the regulation of the cytosolic pH (Rakonczay et al., 2008). An extended exposure to furosemide for 96 h did not reveal any increased inhibition.

In the same test, the saluamine **3** was completely inactive up to 96 h at all investigated concentrations. Exhibiting no toxicity after 24 and 48 h, furfural **2** reduced the cell viability by approximately 20% after 72 h at the maximal concentration of 1000 μ M. As observed with the furosemide, no increased inhibition was observed after extended exposure. Interestingly, pyridinium **4** also began to have an effect after 72 h of exposure. The effect of pyridinium **4** on the cell mortality was increased from 40 to 60% between 72 to 96 h. The concentration at which 50% of the cells survived (EC₅₀) was estimated to be 973 μ M (Fig 3a).

The induction of cell death by exposure to pyridinium **4** was confirmed after evaluation of the caspase-3 activity (Fig 3b). The increased activity (175%) observed after 96 h for the treated cells compared to the untreated ones (100%) allowed the previously observed cell death to be clearly associated with an apoptotic process.

387

388 4. DISCUSSION

389

Anticipating the fate of emerging pollutants often leads to complexity in investigating and researching ETPs, which for the most part remain unknown. By detecting after degradation of a contaminant by environmentally relevant transformations, compounds that have been fully characterized in a previous step, our approach has demonstrated its ability to univocally identify plausible ETPs of organic pollutants. Interestingly, the alternative 395 approach consisting of applying environmentally relevant transformations to a contaminant to 396 obtain, isolate and characterize its plausible ETPs in a single step might seem intuitively 397 quicker and more appropriate. However, the results of this study suggest that such an 398 approach would have failed to detect plausible ETPs exhibiting significantly different 399 physicochemical properties from those of the parent compound, as in the case of pyridinium 400 4. Note that saluamine 3 has already been identified as a biotic TP of furosemide after 401 bioconversion with the fungus Cunninghamella elegans (Hezari and Davis, 1992). The fact 402 that pyridinium 4 was not observed in the same study may be explained by the unavailability 403 of any standard. However, Burka observed the formation of pyridinium 4 after the liver 404 microsomal incubation of furosemide (Chen and Burka, 2007), but this was consecutive to its 405 NMR characterization after the oxidation of furosemide with dimethyldioxirane in deuterated 406 acetone.

407 Because electro-Fenton degradation and bioconversion are representative of the 408 transformations that are likely to occur in the environment, the saluamine 3 and the 409 pyridinium 4, which both result from these two degradation processes, can consequently be 410 considered as plausible ETPs of furosemide. With the help of available standards, the 411 implementation of protocols for the environmental detection of these ETPs can now be 412 initiated. A possible co-product of the oxidation leading to aniline **3**, furfural, is therefore also 413 a plausible ETPs of furosemide. The abundant use of this compound stemming from the 414 biomass for industrial purposes makes it nevertheless an unreliable marker of the presence of 415 furosemide in the environment. Additionally, while the growth-inhibiting properties of 416 furfural have already been mentioned (Almeida et al., 2009), it appears that the concentrations 417 at which furosemide is detected in the environment make the risk associated to its ability to 418 release furfural not significant (Wierckx et al., 2011).

419 By the observation of compounds A, B or C and the collection of their analytical data, 420 our approach has also allowed the identification of new plausible ETPs, including their 421 detection in any complex mixtures. To complete their characterization, their structure 422 proposed on the basis of CID mass spectrum analysis and structural similarities with provided 423 standards, has to be confirmed or refined (which is why they were indicated with letters, not 424 numbers). This confirmation process requires either their isolation from degradation mixtures 425 or their total synthesis (this work is currently underway). Note that each new compound that 426 is isolated and authenticated as a plausible ETP can be subsequently subjected to 427 environmentally relevant transformations and toxicologically evaluated. Such iterative 428 protocol appears appropriate to anticipate further oxidation states of contaminants and thus, to

429 accurately predict their environmental fate, either on a structural or on a toxicological basis. 430 Interestingly, anticipating such further oxidation states of contaminants allowed the 431 environmental fate of furosemide to be reconsidered. Indeed, whereas the anodic oxidation, 432 which is focused on the earlier oxidation states, suggested the aforementioned two distinct 433 degradation pathways (proceeding by oxidation of either the amino group or the furan ring), 434 this study revealed the ability of 4 to release saluamine 3 after over-oxidation of its 435 pyridinium ring. Such information may be of interest for investigating the kinetics of the 436 appearance and disappearance of toxicity associated with the transformation of contaminants 437 in the environment.

438 The final part of this study was devoted to the toxicological evaluation of plausible ETPs, 439 and it highlighted the difference in terms of toxicity between the parent molecules and their 440 ETPs. The present study has consequently confirmed the necessity of developing new 441 methodologies to anticipate the fate of environmental contaminants. Furthermore, this study 442 has also demonstrated the need to provide suitable samples for biological tests, i.e., obtained 443 on preparative scale and isolated. This latter point was demonstrated to be crucial for 444 univocally associating toxicity to a chemical structure. In the case of furosemide, note that if a 445 genotoxicity has already been mentioned, no molecule has yet been clearly associated with it 446 (Rocco et al., 2010; Mondal et al., 2012). To date, only a reactive intermediate in the form of 447 an epoxide has been proposed to explain the cytotoxicity of this drug (Williams et al., 2007). 448 The present work may consequently help the mechanism for the toxicity of furosemide to be 449 reconsidered in relation with one of its TPs.

In summary, our multidisciplinary approach for anticipating the fate of environmental contaminants allowed identifying three plausible ETPs of furosemide, and five other ETPs were observed whose chemical structures must be confirmed or refined. The availability of standards now enables the environmental investigations and, possibly, the quantification of aniline **3** and pyridinium **4**, which appear as relevant markers of the presence of furosemide in the environment.

The biological results also revealed a significant toxicity for the pyridinium **4**. Following this work, assessment of the risk associated with the presence of furosemide in the environment requires a particular focus on this plausible ETP, whose mechanism of action remains unknown and whose ecotoxicity remains to be investigated.

460

461 **5. ACKNOWLEDGMENTS**

- 463 We thank the CNRS for funding (CPDD), MESR for a PhD fellowship and Caroline Bance
- 464 for technical support in microbiology.

- Almeida JRM, Bertilsson M, Gorwa-Grauslund MF, Gorsich S and Liden G (2009) Metabolic
 effects of furaldehydes and impacts on biotechnological processes. *Appl. Microbiol. Biotechnol.* 82:625-638.
 Asha S and Vidyavathi M (2009) Cunninghamella A microbial model for drug metabolism
- 471 studies A review. *Biotechnol. Adv.* 27:16-29.
- 472 Azerad R (1999) Microbial models for drug metabolism. *Adv. Biochem. Eng./Biotechnol.*473 63:169-218.
- 474 Besse J-P and Garric J (2008) Human pharmaceuticals in surface waters. *Toxicol. Lett.*475 176:104-123.
- Brillas E, Sires I and Oturan MA (2009) Electro-Fenton Process and Related Electrochemical
 Technologies Based on Fenton's Reaction Chemistry. *Chem. Rev. (Washington, DC,*U. S.) 109:6570-6631.
- 479 Buchberger WW (2011) Current approaches to trace analysis of pharmaceuticals and personal
 480 care products in the environment. *J. Chromatogr. A* 1218:603-618.
- 481 Castiglioni S, Bagnati R, Fanelli R, Pomati F, Calamari D and Zuccato E (2006) Removal of
 482 Pharmaceuticals in Sewage Treatment Plants in Italy. *Environ. Sci. Technol.* 40:357483 363.
- 484 Celiz MD, Tso J and Aga DS (2009) Pharmaceutical metabolites in the environment:
 485 analytical challenges and ecological risks. *Environ. Toxicol. Chem.* 28:2473-2484.
- 486 Chen L-J and Burka LT (2007) Chemical and Enzymatic Oxidation of Furosemide: Formation
 487 of Pyridinium Salts. *Chem. Res. Toxicol.* 20:1741-1744.
- 488 Daughton CG (2002) Environmental stewardship and drugs as pollutants. *Lancet* 360:1035489 1036.
- 490 Daughton CG and Ternes TA (1999) Pharmaceuticals and personal care products in the
 491 environment: agents of subtle change? *Environ. Health Perspect. Suppl.* 107:907-938.
- 492 Deblonde T, Cossu-Leguille C and Hartemann P (2011) Emerging pollutants in wastewater: A
 493 review of the literature. *Int. J. Hyg. Environ. Health* 214:442-448.
- 494 Dirany A, Efremova Aaron S, Oturan N, Sires I, Oturan MA and Aaron JJ (2011) Study of the
 495 toxicity of sulfamethoxazole and its degradation products in water by a
 496 bioluminescence method during application of the electro-Fenton treatment. *Anal.*497 *Bioanal. Chem.* 400:353-360.
- 498 Dirany A, Sires I, Oturan N and Oturan MA (2010) Electrochemical abatement of the
 499 antibiotic sulfamethoxazole from water. *Chemosphere* 81:594-602.

- 500 Dirany A, Sires I, Oturan N, Ozcan A and Oturan MA (2012) Electrochemical wastewater
 501 treatment for antibiotic sulfachloropyridazine degradation: kinetics, reaction pathways,
 502 and toxicity evolution. *Environ. Sci. Technol.* 46:4074-4082.
- 503 Ericson JF (2010) Evaluation of the OECD 314B Activated Sludge Die-Away Test for
 504 Assessing the Biodegradation of Pharmaceuticals. *Environ. Sci. Technol.* 44:375-381.
- 505 Escher BI and Fenner K (2011) Recent Advances in Environmental Risk Assessment of
 506 Transformation Products. *Environ. Sci. Technol.* 45:3835-3847.
- Fatta-Kassinos D, Meric S and Nikolaou A (2011a) Pharmaceutical residues in environmental
 waters and wastewater: current state of knowledge and future research. *Anal. Bioanal. Chem.* 399:251-275.
- Fatta-Kassinos D, Vasquez MI and Kuemmerer K (2011b) Transformation products of
 pharmaceuticals in surface waters and wastewater formed during photolysis and
 advanced oxidation processes Degradation, elucidation of byproducts and assessment
 of their biological potency. *Chemosphere* 85:693-709.
- Fromentin Y, Grellier P, Wansi JD, Lallemand M-C and Buisson D (2012) Yeast-Mediated
 Xanthone Synthesis through Oxidative Intramolecular Cyclization. *Org. Lett.*14:5054-5057.
- 517 Gauthier H, Yargeau V and Cooper DG (2010) Biodegradation of pharmaceuticals by
 518 Rhodococcus rhodochrous and Aspergillus niger by co-metabolism. *Sci. Total*519 *Environ.* 408:1701-1706.
- Heberer T (2002) Occurrence, fate, and removal of pharmaceutical residues in the aquatic
 environment: a review of recent research data. *Toxicol. Lett.* 131:5-17.
- Henschel KP, Wenzel A, Diedrich M and Fliedner A (1997) Environmental hazard
 assessment of pharmaceuticals. *Regul. Toxicol. Pharmacol.* 25:220-225.
- Hezari M and Davis PJ (1992) Microbial models of mammalian metabolism. N-dealkylation
 of furosemide to yield the mammalian metabolite CSA using Cunninghamella elegans. *Drug Metab. Dispos.* 20:882-888.
- Ibanez M, Sancho JV, Pozo OJ and Hernandez F (2004) Use of Quadrupole Time-of-Flight
 Mass Spectrometry in Environmental Analysis: Elucidation of Transformation
 Products of Triazine Herbicides in Water after UV Exposure. *Anal. Chem.* 76:1328 1335.
- Isidori M, Nardelli A, Parrella A, Pascarella L and Previtera L (2006) A multispecies study to
 assess the toxic and genotoxic effect of pharmaceuticals: Furosemide and its
 photoproduct. *Chemosphere* 63:785-793.

- Joyeau R, Planchon M, Abessolo J, Aissa K, Bance C and Buisson D (2013) Combinatorial
 approach to the selection of active microorganisms in biotransformation: Application
 to sinomenine. J. Mol. Catal. B: Enzym. 85-86:65-70.
- Jurado A, Vazquez-Sune E, Carrera J, Lopez de Alda M, Pujades E and Barcelo D (2012)
 Emerging organic contaminants in groundwater in Spain: A review of sources, recent
 occurrence and fate in a European context. *Sci. Total Environ.* 440:82-94.
- Khalaf H, Salste L, Karlsson P, Ivarsson P, Jass J and Olsson P-E (2009) In vitro analysis of
 inflammatory responses following environmental exposure to pharmaceuticals and
 inland waters. *Sci. Total Environ.* 407:1452-1460.
- 543 Khetan SK and Collins TJ (2007) Human Pharmaceuticals in the Aquatic Environment: A
 544 Challenge to Green Chemistry. *Chem. Rev. (Washington, DC, U. S.)* 107:2319-2364.
- Koopman F, Wierckx N, de WJH and Ruijssenaars HJ (2010) Identification and
 characterization of the furfural and 5-(hydroxymethyl)furfural degradation pathways
 of Cupriavidus basilensis HMF14. *Proc. Natl. Acad. Sci. U. S. A.* 107:4919-4924,
 S4919/4911-S4919/4915.
- 549 Kuemmerer KE (2004) Pharmaceuticals in the Environment: Sources, Fate, Effects and
 550 Risks, Second Edition. Springer GmbH.
- Laurence C, Rivard M, Lachaise I, Bensemhoun J and Martens T (2011) Preparative access to
 transformation products (TPs) of furosemide: a versatile application of anodic
 oxidation. *Tetrahedron* 67:9518-9521.
- Lee WI, Yoon WH, Shin WG, Song IS and Lee MG (1997) Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum. *Biopharm. Drug Dispos.* **18**:753-767.
- Levi Y (2009) Challenges in the assessment and management of health risks associated with emerging water micropollutants. *Bull. Acad. Natl. Med. (Paris, Fr.)* **193:**1331-1344.
- Li W, Josephs JL, Skiles GL and Humphreys WG (2008) Metabolite generation via microbial
 biotransformations with actinomycetes: rapid screening for active strains and
 biosynthesis of important human metabolites of two development-stage compounds,
 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-
- 563 triazaspiro[4.4]non7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101) and
- dasatinib. *Drug Metab. Dispos.* **36:**721-730.
- Lohmann W and Karst U (2008) Biomimetic modeling of oxidative drug metabolism. *Anal. Bioanal. Chem.* 391:79-96.

- Marvalin C and Azerad R (2011) Microbial production of phase I and phase II metabolites of
 propranolol. *Xenobiotica* 41:175-186.
- Mompelat S, Le Bot B and Thomas O (2009) Occurrence and fate of pharmaceutical products
 and by-products, from resource to drinking water. *Environ. Int.* 35:803-814.
- 571 Mondal SC, Tripathi DN, Vikram A, Ramarao P and Jena GB (2012) Furosemide-induced 572 genotoxicity and cytotoxicity in the hepatocytes, but weak genotoxicity in the bone 573 marrow cells of mice. *Fundam. Clin. Pharmacol.* **26**:383-392.
- Oturan MA, Peiroten J, Chartrin P and Acher AJ (2000) Complete Destruction of pNitrophenol in Aqueous Medium by Electro-Fenton Method. *Environ. Sci. Technol.*34:3474-3479.
- Oturan MA, Pinson J, Oturan N and Deprez D (1999) Hydroxylation of aromatic drugs by the
 electro-Fenton method. Formation and identification of the metabolites of Riluzole. *New J. Chem.* 23:793-794.
- 580 Ozcan A, Sahin Y, Koparal AS and Oturan MA (2008) Degradation of picloram by the
 681 electro-Fenton process. *J Hazard Mater* 153:718-727.
- Packer JL, Werner JJ, Latch DE, McNeill K and Arnold WA (2003) Photochemical fate of
 pharmaceuticals in the environment: naproxen, diclofenac, clofibric acid, and
 ibuprofen. *Aquat. Sci.* 65:342-351.
- Rakonczay Z, Jr., Hegyi P, Hasegawa M, Inoue M, You J, Iida A, Ignath I, Alton EWFW,
 Griesenbach U, Ovari G, Vag J, Da PAC, Crawford RM, Varga G, Amaral MD,
 Mehta A, Lonovics J, Argent BE and Gray MA (2008) CFTR gene transfer to human
 cystic fibrosis pancreatic duct cells using a Sendai virus vector. *J Cell Physiol*214:442-455.
- 590 Richardson SD (2010) Environmental Mass Spectrometry: Emerging Contaminants and
 591 Current Issues. Anal. Chem. (Washington, DC, U. S.) 82:4742-4774.
- Rocco L, Frenzilli G, Fusco D, Peluso C and Stingo V (2010) Evaluation of zebrafish DNA
 integrity after exposure to pharmacological agents present in aquatic environments.
 Ecotoxicol. Environ. Saf. 73:1530-1536.
- Rodil R, Quintana JB, Concha-Grana E, Lopez-Mahia P, Muniategui-Lorenzo S and PradaRodriguez D (2012) Emerging pollutants in sewage, surface and drinking water in
 Galicia (NW Spain). *Chemosphere* 86:1040-1049.
- Schulze T, Weiss S, Schymanski E, von der Ohe PC, Schmitt-Jansen M, Altenburger R,
 Streck G and Brack W (2010) Identification of a phytotoxic photo-transformation

- product of diclofenac using effect-directed analysis. *Environ. Pollut. (Oxford, U. K.)*158:1461-1466.
- 602 Sires I, Garrido JA, Rodriguez RM, Brillas E, Oturan N and Oturan MA (2007) Catalytic
 603 behavior of the Fe3+/Fe2+ system in the electro-Fenton degradation of the
 604 antimicrobial chlorophene. *Appl. Catal.*, *B* 72:382-394.
- Sires I, Oturan N and Oturan MA (2010) Electrochemical degradation of Î²-blockers. Studies
 on single and multicomponent synthetic aqueous solutions. *Water Res.* 44:3109-3120.
- 607 Smith RV and Rosazza JP (1975) Microbial models of mammalian metabolism. J. Pharm.
 608 Sci. 64:1737-1759.
- Svanfelt J and Kronberg L (2011) Synthesis of substituted diphenylamines and carbazoles:
 phototransformation products of diclofenac. *Environ. Chem. Lett.* 9:141-144.
- Wierckx N, Koopman F, Ruijssenaars HJ and Winde JH (2011) Microbial degradation of
 furanic compounds: biochemistry, genetics, and impact. *Appl. Microbiol. Biotechnol.*92:1095-1105.
- Williams DP, Antoine DJ, Butler PJ, Jones R, Randle L, Payne A, Howard M, Gardner I,
 Blagg J and Park BK (2007) The metabolism and toxicity of furosemide in the Wistar
 rat and CD-1 mouse: a chemical and biochemical definition of the toxicophore. J. *Pharmacol. Exp. Ther.* 322:1208-1220.
- Ziylan A and Ince NH (2011) The occurrence and fate of anti-inflammatory and analgesic
 pharmaceuticals in sewage and fresh water: Treatability by conventional and nonconventional processes. *J. Hazard. Mater.* 187:24-36.
- 621

Figure captions

Figure 1: Furosemide 1 and its TPs

Figure 2: Structures proposed for a) m/z 345, b) m/z 317 and 282

Figure 3: Cytotoxic evaluation of pyridinium 4. A) Concentration-dependant survival of neuroblastoma cells (SH-SY5Y) exposed for 96 h to pyridinium 4. Percentage survival was calculated using values obtained for untreated cells in the MTT assays as a reference. The calculated EC_{50} was 973±46 μ M. B) The caspase-3 activity was measured after 96 h of treatment with pyridinium 4 (1 mM). Data shown are the mean ± S.E.M. of 3 independent experiments with duplicate wells per experiment,* p<0.05 compared with control.

Figure 1






Figure 2



2: R¹ = H, R² = OH; **3**: R¹ = OH, R² = H.

Figure 3



Supplementary Materials

Anticipating the Fate and Impact of Organic Environmental Contaminants: a New Approach Applied to the Pharmaceutical Furosemide.

Céline Laurencé,^a Michael Rivard,^a Thierry Martens,^{a,*} Christophe Morin,^b Didier Buisson,^c Sophie Bourcier,^d Michel Sablier^{d,e} and Mehmet A. Oturan^{f,*}

^aUniversité Paris-Est, Institut de Chimie et des Matériaux de Paris-Est UMR CNRS UPEC 7182 - 94320 Thiais, France

^bUniversité Paris-Est, Laboratoire Croissance Réparation et Régénération Tissulaires EAC CNRS 7149 - UPEC, 94010 Créteil cedex, France

^cMuséum National d'Histoire Naturelle, Unité Molécules de Communication et Adaptation des Microorganismes, UMR CNRS MNHM 7245 - 75005 Paris, France

^dEcole Polytechnique, Laboratoire des Mécanismes Réactionnels UMR CNRS Ecole Polytechnique 7651 - 91128 Palaiseau cedex, France

^eMuséum National d'Histoire Naturelle, Centre de Recherche sur la Conservation des Collections, USR CNRS MNHN 3224 - 75005 Paris, France

^fUniversité Paris-Est, Laboratoire Géomatériaux et Environnement, EA 4508 UPEMLV, 77454 Marne-la-Vallée, France


* Corresponding authors:

Mehmet A. Oturan Email: <u>mehmet.oturan@univ-paris-est.fr</u> Phone: +33 (0)1 49 32 90 65 Fax: +33(0)1 49 32 91 37 Thierry Martens Email:<u>martens@icmpe.cnrs.fr</u> Phone: +33 (0)1 49 78 11 56 Fax: +33 (0)1 49 78 11 48

Table of contents

1.	Fur	osemide 1 and its oxidation products2	28					
2.	Detection of 3 after electro-Fenton oxidation of 1							
3.	3. Detection of 3 after electro-Fenton oxidation of 4							
4.	4. Detection of 4 after electro-Fenton oxidation and bioconversion of 1							
5. oxic		ection of A after electro-Fenton oxidation and bioconversion of 1 and electro-Fenton n of 4						
6.	Dis	cussion on the structure of m/z 345, RT=5.24 min	34					
6	.1	Expected fragmentations of MH ⁺ deriving from A	\$4					
6	.2	Expected fragmentations of MH ⁺ deriving from A2	\$4					
6	.3	Expected fragmentations of MH ⁺ deriving from A3	\$5					
6	.4	Expected fragmentations of MH ⁺ deriving from A4	35					
6	.5	Expected fragmentations of MH ⁺ deriving from A5	\$6					
7.	Det	ection of B1 and B2 or C3 after electro-Fenton oxidation of 1 and 4	\$7					
8.	Dis	cussion on the structures of m/z 317, RT=4.0 and 7.0 min	\$7					
8	.1	Expected fragmentations of MH ⁺ deriving from B1	\$8					
8	.2	Expected fragmentations of MH ⁺ deriving from B2	\$8					
8	.3	Expected fragmentations of MH ⁺ deriving from B3	;9					
8	.4	Expected fragmentations of MH ⁺ deriving from B4	39					
8	.5	Expected fragmentations of MH ⁺ deriving from B5 4	10					
9. elec		ection of C1 and C2 or C3 after electro-Fenton oxidation and bioconversion of 1 and Fenton oxidation of 4						
10.	Dis	cussion on the structures of m/z 282, RT=4.2 and 10.4 min	1					
1	0.1	Expected fragmentations of MH ⁺ deriving from C14	12					
1	0.2	Expected fragmentations of MH ⁺ deriving from C24	12					
1	0.3	Expected fragmentations of MH ⁺ deriving from C34	12					
1	0.4	Expected fragmentations of MH ⁺ deriving from C44	13					
1	0.5	Expected fragmentations of MH ⁺ deriving from C54	13					

1. Furosemide 1 and its oxidation products



Oxid ation prod	R T (M H ⁺ m	Exp mas	The o. mas	m Da	p pm	D BE ¹	Elemental compositi on		Dete n ²	ctio
ucts	min)	/z	S	S					a)	b)	c)
3	5	2	250.	250.	1	5	4	C7H8ClN2			
	.2	51	9906	9893	.3	.2	.5	O_4S			
4	2	3	328.	328.	0	0	8	$C_{12}H_{10}ClN$			
	.2	29	9999	9999			.5	$_2O_5S$			
Α	5	3	344.	344.	0	0	8	$C_{12}H_{10}ClN$			
	.24	45	9948	9948			.5	$_2O_6S$			
B 1	7	3	317.	317.	-	-	7	$C_{11}H_{10}ClN$			

	.0	17	0005	0024 1.9		6	.5	$_{2}O_{5}S$
B2or	4	3	316.	317.	-	-	7	$C_{11}H_{10}ClN$
3	.0	17	9997	9999	0.2	0.6	.5	$_{2}O_{5}S$
C1	1	2	282.	282.	0	2	8	C ₁₂ H ₉ ClN
	0.4	82	0176	0169	.7	.5	.5	O_5
C2or	4	2	282.	282.	-	-	8	C ₁₂ H ₉ ClN
3	.2	82	0168	0169	0.1	0.4	.5	O_5

¹DBE: Double Bond Equivalency. ²Detection (+) during: (a) electro-Fenton oxidation of furosemide **1**, (b) electro-Fenton oxidation of pyridinium **4**, (c) bioconversion of furosemide **1**.

2. Detection of 3 after electro-Fenton oxidation of 1





Fig. SM-1. (a) Extracted ion chromatogram (positive ion current) of m/z 251 for electro-Fenton oxidation of furosemide **1**. (b) CID mass spectrum of protonated molecular ion of compound **3** (MH⁺ m/z 251), cone =25 V, Ecol = 10 eV. The CID spectrum of the ion at m/z 251 (RT=5.2 min) is the same as that obtained for the MH⁺ of compound **3**.

3. Detection of 3 after electro-Fenton oxidation of 4






Fig. SM-2. (a) Extracted ion chromatogram (positive ion current) of m/z 251 for electro-Fenton oxidation of pyridinium 4. (b) CID mass spectra of ion at m/z 251 at RT=5.2 min. Cone=25 V, Ecol = 15 eV.

4. Detection of 4 after electro-Fenton oxidation and bioconversion of 1





Fig. SM-3. Extracted ion chromatograms (positive ion current) of m/z 329 for (a), (b) and (c) samples. (d) CID mass spectrum of m/z 329 ion at RT=2.2 min. Cone =25 V, Ecol=10 eV. This CID mass spectrum is the same for both samples (a) and (b) and corresponds to that of the pyridinium **4**.




5. Detection of A after electro-Fenton oxidation and bioconversion of 1 and electro-Fenton oxidation of 4


Fig. SM-4. Extracted ion chromatograms (positive ion current) of m/z 345 for (a), (b) and (c) samples. (d) CID mass spectra of MH^+ of compounds at m/z 345 (at RT=5.24 min). Cone=25 V, Ecol=15 eV. The selection of MH^+ is made only on ³⁵Cl isotope atom. Ions at m/z 327, 299, 271, 243 have preserved chlorine atom.

6. Discussion on the structure of m/z 345, RT=5.24 min


The elemental composition of the protonated molecular ion, eluted at RT=5.24 min, is $C_{12}H_{10}ClN_2O_6S$. This compound is corresponding to an oxidized form of pyridinium 4. The protonated molecular ion loses one water molecule and one, two or three molecules of carbon monoxide to give ions at m/z 299, m/z 271 or m/z 243 respectively. Among the five possible structures A, A2, A3, A4 and A5, only A revealed to be in agreement with the fragmentations observed.



6.1 Expected fragmentations of MH⁺ deriving from A




6.2 Expected fragmentations of MH⁺ deriving from A2




Ion at m/z 291 is not observed and m/z 299 does not allow the formation of ions observed at m/z 271 and m/z 243.

6.3 Expected fragmentations of MH⁺ deriving from A3




Ion at m/z 299 does not allow the formation of ion m/z 271.


6.4 Expected fragmentations of MH⁺ deriving from A4



Ions at m/z 299 and m/z 271 do not allow the formation of ion at m/z 243. Ion at m/z 317 is not observed.



Ion at m/z 271 does not allow the formation of ion at m/z 243.




7. Detection of B1 and B2 or B3 after electro-Fenton oxidation of 1 and 4

Fig. SM-5. Extracted ion chromatograms (positive ion current) of m/z 317 for electro-Fenton oxidation of (a) furosemide **1** and (b) electro-Fenton oxidation of pyridinium **4**. CID mass spectra of ion at m/z 317 at (c) RT=4.0 min and (d) RT=7.0 min. Cone=25 V, Ecol=15 eV.


8. Discussion on the structures of m/z 317, RT=4.0 and 7.0 min

The elemental composition of both protonated molecular ions at m/z 317 is $C_{11}H_{10}CIN_2O_5S$. They lost a carbon and an oxygen atom relative to the pyridinium 4. We assume that the CO of carboxylic function was lost. Five structures **B1**, **B2**, **B3**, **B4** and **B5** have been considered. **B1** is in agreement with the CID mass spectrum of MH⁺ obtained for


the compound eluted at 7 min. **B2** and **B3** both allow the formation of ions observed for the decomposition of MH^+ eluted at 4.0 min.




8.1 Expected fragmentations of MH⁺ deriving from B1



8.2 Expected fragmentations of MH⁺ deriving from B2




8.3 Expected fragmentations of MH⁺ deriving from B3



8.4 Expected fragmentations of MH⁺ deriving from B4

The fragmentation of $B4H^+$ leads to the elimination of one or two molecules of CHCOH to form the ions at m/z 275 and m/z 233 respectively. These ions are unobserved on CID mass spectra of m/z 317 (see 10.3).

8.5 Expected fragmentations of MH⁺ deriving from B5



The proposed fragmentation of $B5H^+$ leads to the formation of two ions unobserved on CID mass spectra of m/z 317.

9. Detection of C1 and C2 or C3 after electro-Fenton oxidation and bioconversion of 1 and electro-Fenton oxidation of 4






Fig. SM-6. (a) Extracted ion chromatogram (positive ion current) of m/z 282 for electro-Fenton oxidation of pyridinium 4. CID mass spectra of ion at m/z 282 at (b) RT=4.2 min and (c) RT=10.4 min. Cone=25 V, Ecol=15 eV.

10. Discussion on the structures of m/z 282, RT=4.2 and 10.4 min


Structural characterization led to focus on the five compounds C1, C2, C3, C4 and C5. C1 is in agreement with fragmentations observed for RT = 10.4 min. Structures C2 and C3 both allow the formation of ions observed for the decomposition of MH⁺ eluted at 4.2 min.




10.1 Expected fragmentations of MH⁺ deriving from C1




10.2 Expected fragmentations of MH⁺ deriving from C2



10.3 Expected fragmentations of MH⁺ deriving from C3



10.4 Expected fragmentations of MH⁺ deriving from C4



The fragmentation of C4H⁺ leads to the ions at m/z 254 and m/z 198 unobserved on CID mass spectra of m/z 282.

10.5 Expected fragmentations of MH⁺ deriving from C5

